Applications published 18 February 2009

Fixed combination dosage forms for the treatment of migraine
Proethic Pharmaceuticals; APR Applied Pharma Research 2023894*

• Pharmaceutical compsns for vein irritating drugs
Adventrx Pharmaceuticals 2032895*

• A compsn for inactivating an enveloped virus
Viroblock 2023896*

• Preparation of an antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
Georgetown University 2023897*

• Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compsns
Evonik Degussa 2023898*

• Controlled dose drug delivery system
Shire LLC 2023900*

• Pharmaceutical compsn comprising tetrahydrolipstatin
LEK Pharmaceuticals 2023901*

• DPP IV inhibitor formulations
Boehringer Ingelheim International 2023902*

• Process for the preparation and surface coating of pellets
Egis Gyogyszergyar 2023903*

• Sustained release coated tablet with precisely regulated release profile
Zaklady Farmaceutyczne “Polpharma” 2023904*

• Passive time released solute treatment
Sonoma Holdings 2023905*

• Delayed-release compsns of extended release forms of venlafaxine
Neurosci 2023906*

• Transdermal delivery system comprising sufentanil and its analogues
Labtec Gesellschaft fuer Technologische Forschung und Entwicklung 2023907*

• Multi-layer medical patch with impermeable centre
Oramelts International 2023908*

• Muscarinic agonists to treat impulse control disorders
Solvay Pharmaceuticals 2023909*

• AH receptor antagonists
Symrise 2023910*

• Compounds A-R-X for the manufacture of pharmaceutical preparations
Mueller-Enoch 2023911*

• Methods and compsns using immunomodulatory compounds in combination therapy
Celgene 2023912*

• Methods for treating blood disorders
Colorado State University Research Foundation 2023913*

• Methods of treating a neurological disorder with creatine monohydrate
Avicena Group 2023914*

• Borrelidin derivatives as antiproliferative agents and angiogenesis inhibitors
Biotica Technology 2023915*

• Acidic compsn
Pfeinsmith 2023916*

• Method for the treatment and prevention of ocular disorders
Scynexis 2023918*

• Compounds and amyloid probes thereof for therapeutic and imaging uses
Molecular Neuroimaging 2023919*

• Cannabinoid receptor agonists
Jenrin Discovery 2023920*

• Inhibition of adenylyl cyclase for treating a disorder of the circadian rhythm
Medical Research Council 2023921*

• Triazole derivatives II
Merck Patent 2023922*

• Use of ixabepilone in combination with CYP3A4 inhibitors for pharmaceuticals
Bristol-Myers Squibb 2023923*

• Aryl-fused spirocyclic compounds
Merck 2023924*

• CDK1 pathway inhibitors as selective inhibitors of tumour cell growth
Senex Biotechnology 2023925*

• Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
Bayer Healthcare 2023926*

• Deoxynojirimycin and D-arabinitol analogues and methods of using
United Therapeutics 2023927*

• Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
McNeil 2023928*

• Ionisable inhibitors of fatty acid amide hydrolase
NV Organon 2023930*

• Anticancer treatments with a combination of docotaxel and ecteinascidin
Pharma Mar 2023931*

• Methods for preventing or treating acute and chronic pain
Trustees of Dartmouth College 2023932*

• Acetylenic heteroaryl compounds
Ariad Pharmaceuticals 2023933*

• 3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors
Janssen Pharmaceutica 2023934*

• Drug administration methods
Cylene Pharmaceuticals 2023935*

• Compsns and their uses directed to PTPR alpha
Isis Pharmaceuticals 2023936*

• RNAI modulation of AHA and their therapeutic uses thereof
Alnylam Pharmaceuticals; The Scripps Research Institute 2023937*

• Modulation of CHREBP expression
Isis Pharmaceuticals 2023938*

• Compounds and methods for modulating expression of PCSK9
Isis Pharmaceuticals 2023939*

• Compounds and methods for modulating expression of SGLT2
Isis Pharmaceuticals 2023940*

• Protein crosslinkers, crosslinking methods and applications thereof
Incept 2023941*

• Mixtures of tannins, their production and use in medicaments or disinfectants
BASF 2023942*

• Methods for treating diabetes
Tulane University 2023943*

• Pre-8 cell proliferation and lymphoblastic leukaemia/ high-grade lymphoma in MIR155 transgenic mice
Ohio State University Research Foundation 2023944*

• Compsn for improving eye health
The Iams Company 2023945*

• Inhibition of a gliotoxin
Max-planck-Gesellschaft zur Foerderung der Wissenschaften 2023946*

• Compsn and method for increasing cell permeability of a compound
SmithKline Beecham 2032947*

• Use of cyclosporin A or melle4-cyclosporin for the treatment of acute myocardial infarction
Ovize, Michel 2023948*

• Compsns and methods for convection enhanced delivery of high molecular weight neurotherapeutics
The Regents of the University of California 2023949*

• Urodilatin cancer treatment
University of South Florida 2023950*

• Prostate epithelial androgen suppresses prostate growth and tumour invasion
University of Rochester 2023951*

• Inducing immune responses to influenza virus using polypeptide and nucleic acid compsns
Pharmexa 2023952*

• Immunological compsn
Sanofi Pasteur 2023954*

• Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
Tolerrx 2023955*

• Pharmaceutical combinations comprising a MTOR inhibitor and a RAF kinase inhibitor
Novartis 2023956*

• Oral liquid loratadine formulations and methods
Morton Grove Pharmaceuticals 2023957*

• Pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
McNeil 2023958*

• Polyethylene glycol-interferon alpha conjugate
Dong-A Pharm 2023959*

• Conjugates of azaridinyl-epothilone analogues and pharmaceutical compsns comprising same
Bristol-Myers Squibb 2023960*

• Method for isolating homogeneous populations of transduced progenitors stably expressing specific levels of a transgene
Banfi, Andrea; Misteli, Heidi 2023961*

• Human OCT-2 variant peptide chains, nucleic acids, and methods
Centocor 2023962*